Trial Profile
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- Acronyms SVALMEL
- 19 Jun 2018 New trial record